Brian Rini on Muck Rack

Brian Rini

Verified
Nashville
As seen in: GU Oncology Now, The Uromigos, Nature, Educational Studies, Expert Review of Anticancer Therapy, Biomed Central (BMC), JAMA Oncology, Medscape, The New England Journal of Medicine, Cleveland Clinic Health Essentials Podcast, Cell Press, Consult QD and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Brian

Contact Brian, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

ASCO 2026 GU Highlights & FDA Approvals with Drs. Brian Rini & Tom Powles (The Uromigos)

|
By Brian Rini Verified, Tom Powles
| oncbrothers.com
PROTEUS: trial comparing ADT monotherapy to apalutamide plus ADT in high-risk localized prostate cancer. We explored its findings, implications, and the ongoing debate surrounding its control arm TALAPRO-3 Study: impact of PARP inhibitors combined with enzalutamide in metastatic castration-sensitive prostate cancer with homologous recombination repair (HRR) mutations. We discussed the nuances of HRR mutations and their clinical significance.
Open in Who Shared Issue with article?

ASCO 2026: Discussant - Living Longer, Living Better: Can We Have It All?

|
By Rashid K. Sayyid, Brian Rini Verified
| UroToday Verified
(UroToday.com) The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting was host to a session on new approaches to curing bladder and kidney cancer.
Open in Who Shared Issue with article?

Insights in Renal Cell Carcinoma From ASCO GU 2026

|
By Brian Rini Verified
| Medscape Verified
A range of clinically impactful studies in renal cell carcinoma (RCC), presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium, underscore the growing promise of hypoxia-inducible factor-2 alpha (HIF-2α) inhibition in this condition, as discussed by Dr Brian Rini of Vanderbilt University School of Medicine in Nashville, Tennessee, who offers insights into these and other abstracts. Dr Rini begins by highlighting two phase 3 trials.
Open in Who Shared Issue with article?
See all 112 licensed articles (175 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified